Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus

NCT03707171 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide affects thinking and memory in adults with type 2 diabetes over a 12-week period.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18–80 · all sexes

Timeline Started 2018-10 · est. completion 2019-05

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03707171 ↗

Description as written by the study sponsor.

Type 2 diabetes mellitus (T2DM) can impaire cognitive function,the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.Cognitive impairment seriously affects the health and quality of life of the elderly. Prevention and treatment measures for cognitive decline in persons with T2DM has not been well studied. Glucagon-like peptide-1 (GLP-1) is a member of an endogenous class of incretin hormones synthesized in intestinal epithelial L-cells.GLP-1 enhances glucose-dependent secretion of insulin,inhibits glucagon secretion, slows gastric emptying and reduces food intake. Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM. The effect on BMI,waist circumference, hip circumference, waist-to-hip ratio,fasting plasma glucose，glycosylated hemoglobin,blood lipids and cognitive function were measured to explore the effects of liraglutide in patients with T2DM. The overall goal of this study is to explore the effects of liraglutide on the cognitive function in patients with type 2 diabetes mellitus and make further contribution to the improvement of cognitive function.

Treatments tested

Liraglutide Drug

Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
placebo Drug

Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.

Main thing measured	Changes of cognitive function assessed by cognitive function scale after 12 weeks.
Sponsor	Third Military Medical University
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03707171 ↗